Nicolas Durand is the founder and CEO of Abionic SA, the company that developed the fastest in vitrodiagnostic platform in the world, the abioSCOPE. He holds an aerobatic pilot’s certificate and is a member of the board of directors at the Vaudois Chamber of Commerce and Industry, as well as being an Intelligence Officer in the Swiss Armed Forces. A micro engineering graduate of the EFPL, his doctoral work blossomed into several publications and patents that became the source of Abionic’s technology.
Watch an extract from the interview
Do you think that politicians have given the medical establishment free rein?
Sadly, I do think we’ve heard a bit too much from them in general. There are three categories of people that we probably shouldn’t have put together: politicians, doctors and journalists. Putting these three together builds the exact vicious circle needed to create a society where the objective is to incur zero risk, which recommends that we live in a hermetically sealed atmosphere.
Getting back to Abionic, I daresay the crisis has given you a few challenges. Did you have to reprioritise, and if yes, how so?
In the beginning, it was a huge problem: we were planning to do some significant fundraising and the minute the crisis began, all the potential investors that were interested rejected the opportunity almost overnight. The fact that we had to stop travelling also put the breaks on our commercialisation plans. We couldn’t visit doctors to present them with our products any more, they were all completely obsessed with the coronavirus.
Have you found a new way to keep your sales going, without visiting clients?
The plus in this crisis has been that it’s forced everyone to take steps towards digitalisation. We have been able to find solutions together with doctors who have a more avant-garde approach and who are open to testing out new technology, but sadly, they do not represent the majority of the profession.
The plus in this crisis has been that it’s forced everyone to take steps towards digitalization.
So, digitalization has been accelerated, thanks to the crisis. Has it also created other opportunities?
We’ve oriented ourselves towards developing a severity test for corona patients which could be useful, as the majority of patients in whom the disease is fatal have viral sepsis (cytokine storms), which is the cause of death. We wanted to supply our machines to laboratories and doctors in the region for free. We were very frustrated and disappointed that our offer was met with almost total refusal. In the history of humanity, innovation has always been key in getting crises under control, but now, it’s a shock to see that innovation has been pushed into the background. We have mainly worked with foreign hospitals who have been brave enough to try the machines and have been won over. You can count the companies certified in the diagnostic sector in Switzerland on one or two hands, but we still haven’t been taken seriously.
In the history of humanity, innovation has always been key in getting crises under control, but now, it’s a shock to see that innovation has been pushed into the background.
How do you manage this frustration while maintaining the team’s levels of motivation?
Our associates are getting up in the morning and going out to save lives. Our sepsis test really could save several million people every year. However, even with this amazing technology that can help the patient, we have noticed that many people are fighting against it. We are trying to work as positively and collaboratively as possible, but sometimes we have to accept that it simply won’t happen and concentrate on the segments that are most open to this level of technology.
Have you put special measures in place to support the team?
Two-thirds of our team are biologists and production technicians, and we currently don’t have the possibility of executing production work from home, so they have had to come in, but we did consider home office for the management team. Most of them come in to work every day because they like being around their colleagues and in our work environment, which complies with the hygiene standards. This enables us to have a social outlet, which is vital in a company like ours.
So, the company’s mission is strong enough to keep the team motivated?
Definitely. Our associates know that we never make a decision just for its own sake – we are looking to simplify their lives. We have built up a trusting relationship with them, which is absolutely key.
What would you tell yourself if you could go back in time to a year ago?
The pilot in me would say: hold on tight, it’s going to be a bumpy ride, but we’ll come out of it stronger than ever.
Does the “new normal” apply to your sector?
Our industry is essential enough to continue its activities in as normal a manner as possible. Apart from travelling, nothing has fundamentally changed.
Have your customers’ expectations changed?
Yes, we’ve noticed that there has been a focus on COVID, although the needs in the sepsis sector are far greater with 11 million deaths per year. However, getting a point of care system onto the market when the laboratories have got a firm grip on the entire diagnostic sector can’t be done overnight, especially in a crisis.
What are Abionic’s objectives in the short, medium and long term?
In the short term, we want to achieve commercial success with the sepsis tests. We have mainly pushed forward on the marketing front in Europe and Asia, and we are now targeting the USA and other key markets.
So you haven’t been hit in a major way, ultimately?
I’ve had to fight to ensure that we haven’t been hit by the crisis, because a lot of our shareholders really wanted us to tighten our belts. Along with the board of directors, we had to insist on not reducing our activities too much and had to explain that excessively diminishing the company’s main asset, human capital, would drain its lifeblood. We got caught up in a panic. People generally say that when you spend less, you can keep going for longer. That isn’t necessarily good mathematics, as the point of our business is also to be able to hit the ground running again as soon as the crisis has passed. However, if we lose our substance, that will be very difficult to do.
How do you manage uncertainty?
I am not sure whether you can manage uncertainty, by definition. Our motto has always been perseverance through resilience. We are tenacious, we fight, we stick with it till the end, we really want to change the world for the better. Yes, it’s complicated, yes, it’s tough, but in the end, that won’t matter: we’ll get there. That’s what motivates us, that’s what makes us wake up in the morning with a smile.
Is resilience innate or can you learn it?
From my point of view, learning how to be resilient is like learning a new language. Even those who aren’t gifted will learn, if they are immersed in it for a long enough period of time. We simply don’t have the choice, and we are forced to adapt.
From my point of view, learning how to be resilient is like learning a new language. Even those who aren’t gifted will learn, if they are immersed in it for a long enough period of time.
We have heard a lot about the importance of social responsibility, of giving back to society in general. Is that something that’s important to you?
Yes, of course. When we, my co-founder Iwan Märki and I, decided to create Abonic, we decided to do it here for the good of Swiss society. In the context of the current crisis, we immediately decided to contribute by giving our tests and machines to hospitals to help them withstand it, and we offered them for free. This desire to do something for society is definitely a huge part of what we do.
Do you have any sustainable development objectives here at Abionic?
Today, the themes of sustainable development and ecology are definitely key. Naturally, we are trying to integrate these concepts into all of our ideas in every way we can, but our main mission is to help people benefit from our tests and survive sepsis. It’s hard to be perfect through and through, especially in the launch and growth phases.
Any final words on this subject?
In this country, which is the number one in innovation, we’d like to encourage people to be more optimistic and braver when it comes to new technology. I think we need to start taking start-ups that can make a positive difference in our society more seriously, without always just seeing the risks.
More interviews and articles from the #EYnewnormal magazine
«From a business perspective, what was your initial response in managing this crisis?»READ MORE
«How do you maintain strong relationships with customers during these times?»READ MORE
«Why do you think companies are so creative and flexible in times of crisis?»READ MORE
Dr. Jürg Wittwer
«What can companies do to cope with the high level of uncertainty right now?»READ MORE
«What opportunities have arisen for companies in the last three to four months?»READ MORE
«As the initial panic subsides, how would you describe the current mood and how are you responding?»READ MORE
Our latest thinking
Here you’ll find the most relevant EY insights to help you navigate through the COVID-19 crisis – and beyond:
11 June 2021
IBOR Transition: Regulatory and industry-led market developments in May 2021
The transition from Interbank Offered Rates (IBOR) to Alternative Risk-Free Rates (RFRs) has an impact on all financial and non-financial institutions operating with the impacted floating reference rates. It affects a wide range of financial instruments on the derivative and cash markets.
10 June 2021
Entry into force of the revised Insurance Contract Act (VVG) on 1 January 2022 – overcoming challenges and exploiting opportunities
The Federal Council has decided that the revised Insurance Contract Act will enter into force on 1 January 2022. Insurance companies have until the end of this year to make the necessary adaptations, whereby careful assessment and implementation of the new requirements are fundamental.
17 May 2021
Valuation Market Essentials Switzerland Q1 2021
How did the market and M&A activity develop in the first quarter of 2021 considering high degree of uncertainty and strong volatility in the stock market in 2020?
7 May 2021
COVID-19 | Emissionsabgaberechtliche Aspekte bei Sanierungen
Aufgrund der aktuellen Situation geraten mehr und mehr Unternehmen in finanzielle Schieflage. Dies führt häufig zu Unterbilanzen und zur Notwendigkeit von Sanierungsmassnahmen i.S.v. Art. 725 OR.
Are you our next interview partner?
The New Normal Magazine is open for thought leaders and decision makers.Contact us